Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | MELK | Q14680 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7850413 | 0.98 | ALDH1A1 (0.64) | ALDH1A1KDM4EMAPTACHEMELK | |
| SCHEMBL1026913 | 0.90 | ALDH1A1 (0.59) | ALDH1A1KDM4EMAPTMELKPNMT | |
| SCHEMBL29589725 | 0.90 | ALDH1A1 (0.59) | ALDH1A1KDM4EMAPTMELKPNMT | |
| Hydrochloric Acid SCHEMBL15671006 | 0.88 | ALDH1A1 (0.58) | ALDH1A1KDM4EMAPTMELKPNMT | |
| SCHEMBL1026101 | 0.83 | ALDH1A1 (0.59) | ALDH1A1KDM4EMAPTMELKPNMT | |
| SCHEMBL30428318 | 0.83 | ALDH1A1 (0.59) | ALDH1A1KDM4EMAPTMELKPNMT | |
| SCHEMBL383984 | 0.82 | ALDH1A1 (0.57) | ALDH1A1KDM4EMAPTSRD5A2SRD5A1 | |
| SCHEMBL30831371 | 0.82 | ALDH1A1 (0.57) | ALDH1A1KDM4EMAPTSRD5A2SRD5A1 | |
| SCHEMBL12486922 | 0.81 | MELK (0.44) | ALDH1A1ACHEMELKSYKSRD5A2 | |
| Hydrochloric Acid SCHEMBL22654009 | 0.81 | ALDH1A1 (0.58) | ALDH1A1KDM4EMAPTMELKPNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| EP-2742039-B1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2015-09-16 | — | — | EP | disclosed |
| US-8871756-B2 | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease | HOFFMANN-LA ROCHE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2742039-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN-LA ROCHE INC. | 2013-08-01 | — | — | US | disclosed |
| WO-2013020993-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | WO | disclosed |
| US-20070232538-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20040063699-A1 | Gpr14 antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20040053826-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-1308513-A1 | USE OF POLYPEPTIDE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | CFTR, H1-10, RECQL | ALDH1A1 2189/4885KDM4E 3397/4885MAPT 4392/4885 |
| US-20070232538-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | ALDH1A1 3946/4885KDM4E 4438/4885MAPT 2628/4885 |
| US-20040053826-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | ALDH1A1 3946/4885KDM4E 4438/4885MAPT 2628/4885 |
| US-20040063699-A1 | Gpr14 antagonist | GPR142, GPR139, GPR4 | ALDH1A1 2561/4885KDM4E 2148/4885MAPT 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.